Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for prevention of anti-TB drug-induced hepatotoxicity
NCT02889757Phase 4Unknown
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of acetylcysteine in drug induced liver injury (DILI), sponsored by Far Eastern Memorial Hospital. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT02889757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889757.